Celltrion’s Rituximab Biosimilar Has Easy US FDA Panel Ride Despite Questions About Narrow Label

 
• By Sue Sutter
  
FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers